Related references
Note: Only part of the references are listed.Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy
Mark S. Moehle et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
Discovery of Selective M4 Muscarinic Acetylcholine Receptor Agonists with Novel Carbamate Isosteres
Qingyi Yang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders
Mark S. Moehle et al.
MOVEMENT DISORDERS (2019)
The neurobiological basis for novel experimental therapeutics in dystonia
Anthony M. Downs et al.
NEUROBIOLOGY OF DISEASE (2019)
Crystal structure of the M5 muscarinic acetylcholine receptor
Ziva Vuckovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Applications of Deuterium in Medicinal Chemistry
Tracey Pirali et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease
Joseph D. Panarese et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Allosteric modulators targeting CNS muscarinic receptors
Andreas Bock et al.
NEUROPHARMACOLOGY (2018)
Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists
Hongtao Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists
Aaron M. Bender et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype
Aaron M. Bender et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Applications of Palladium-Catalyzed C-N Cross-Coupling Reactions
Paula Ruiz-Castillo et al.
CHEMICAL REVIEWS (2016)
Characterization of PCS1055, a novel muscarinic M4 receptor antagonist
Carrie H. Croy et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
Crystal structures of the M1 and M4 muscarinic acetylcholine receptors
David M. Thal et al.
NATURE (2016)
Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release
Daniel J. Foster et al.
NEURON (2016)
Experimentally Validated hERG Pharmacophore Models as Cardiotoxicity Prediction Tools
Jadel M. Kratz et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile
Mikhail F. Gordeev et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Muscarinic acetylcholine receptors: novel opportunities for drug development
Andrew C. Kruse et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc
Remy C. Lemoine et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes
Tang Peng Cho et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Synthesis, Affinity Profile and Functional Activity of Potent Chiral Muscarinic Antagonists with a Pyrrolidinylfuran Structure
Serena Scapecchi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Juergen Wess et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Synthesis and pharmacology of benzoxazines as highly selective antagonists at M4 muscarinic receptors
TM Böhme et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Share Paper
